PULMATRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On January 30, 2020, Pulmatrix, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to Pulmazole, the Company's inhaled itraconazole antifungal being developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



             Exhibit No.   Description

                99.1         Press Release dated January 30, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses